Malignant neoplasm progression: FDA reporting patterns
100,504 FDA FAERS reports mention Malignant neoplasm progression. 98,306 reports have a serious outcome flag.
Medicines named as suspect
- Pembrolizumab: 11,429 reports
- Nivolumab: 9,708 reports
- Enzalutamide: 5,348 reports
- Carboplatin: 5,058 reports
- Everolimus: 4,468 reports
- Paclitaxel: 4,334 reports
- Letrozole: 3,961 reports
- Ipilimumab: 3,724 reports
- Fulvestrant: 3,577 reports
- Gemcitabine: 3,466 reports
- Capecitabine: 3,437 reports
- Cabozantinib: 3,431 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.